07 December 2023
07 December 2023
Emraclidine is a late-stage antipsychotic asset of Cerevel being analysed for the treatment of schizophrenia.
IGM will lay off 22% of its staff and suspend four clinical activities to advance autoimmune diseases and colorectal cancer programmes.
CG Oncology has received the fast track and breakthrough designations needed to accelerate US FDA submission.
Coya can earn milestone payments based on sales, with a maximum of $677.25m linked to tiers of cumulative net sales milestones.
The Phase Ib trial will evaluate the combination therapy of Welireg and HC-7366 in patients with clear cell renal cell carcinoma.
AbbVie will pay $30m upfront and up to approximately $325m in milestone-based payments for treatments in neuroscience and oncology.
The approval is based on interim data from the Phase III KarMMa-3 clinical trial of Abecma in RRMM patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline.
Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials.
Give your business an edge with our leading industry insights.
